MIRCERA

Clinical Study Highlights

The efficacy and safety of MIRCERA has been evaluated in four phase II and six phase III correction and maintenance studies. More than 2,700 patients participated in the largest phase II–III registration programme ever conducted for a drug treating renal anaemia.1

Please click on the following links to get an overview of the correction and maintenance studies in patients with CKD-associated anaemia.

Information on clinical trials sponsored by F. Hoffmann-La Roche can be found on the Clinical Trial Protocol Registry and Results Database

References:
1. MIRCERA® Summary of Product Characteristics. F. Hoffmann-La Roche Ltd. 2007.

Please Log in
Free registration to access disease diagnosis, patient management, physician tools.

Only registered users have access to this content.

Already Registered?

Email    Password   

Not a member?

Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students. 

Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major theraputic areas, disease management, and clinical tools.

As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!

REGISTER today it only takes a minute! and it's FREE

If you are not a healthcare professional please visit our patient site.

Having problems?

Use our forgotten password facility or email us at: contact@epgonline.org

Exit Log in